Seeking common pathophysiology in asthma, atopy and sinusitis

Trends in Immunology

Volumn 32, Issue 2, 2011, Pages 43-49

  Porter, Paul C ^a   Ongeri, Valentine ^a   Luong, Amber ^b   Kheradmand, Farrah ^a   Corry, David B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIINFECTIVE AGENT; CYTOKINE; FLUCONAZOLE; ITRACONAZOLE; PROTEINASE;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ASTHMA; ATOPY; CELL FUNCTION; CHRONIC SINUSITIS; DISEASE ASSOCIATION; FUNGUS; HUMAN; IMMUNE RESPONSE; MYCOSIS; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT DISEASE; SERODIAGNOSIS; SHORT SURVEY; TH2 CELL;

ANIMALS; ASTHMA; DERMATITIS, ATOPIC; HUMANS; PROGNOSIS; SINUSITIS; TH2 CELLS;

EID: 79751538589     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2010.11.007     Document Type: Short Survey

References (81)

1. Horn B.R., et al. Total eosinophil counts in the management of bronchial asthma. N. Engl. J. Med. 1975, 292:1152-1155.
2. Johansson S.G. Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet 1967, 2:951-953.
3. Bradley B.L., et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J. Allergy Clin. Immunol. 1991, 88:661-674.
4. Robinson D.S., et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 1992, 326:298-304.
5. Corry D.B., et al. Requirements for allergen-induced airway hyperreactivity in T and B cell-deficient mice. Mol. Med. 1998, 4:344-355.
6. Grunig G., et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998, 282:2261-2263.
7. Gavett S.H., et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am. J. Physiol. 1997, 272:L253-L261.
8. Keane-Myers A., et al. B7-CD28/CTLA-4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens. J. Immunol. 1997, 158:2042-2049.
9. Wills-Karp M., et al. Interleukin-13: central mediator of allergic asthma. Science 1998, 282:2258-2261.
10. Corry D.B., et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J. Exp. Med. 1996, 183:109-117.
11. Corry D.B. Emerging immune targets for the therapy of allergic asthma. Nat. Rev. Drug Discov. 2002, 1:55-64.
12. Ramsey C.D., Celedon J.C. The hygiene hypothesis and asthma. Curr. Opin. Pulm. Med. 2005, 11:14-20.
13. Pepys J., et al. Allergic reactions of the lungs to enzymes of Bacillus subtilis. Lancet 1969, 1:1181-1184.
14. Pepys J. Immunological and clinical findings in workers and consumers exposed to enzymes of Bacillus subtilis. Proc. R. Soc. Med. 1973, 66:930-932.
15. Pepys J., et al. Clinical and immunological responses to enzymes of Bacillus subtilis in factory workers and consumers. Clin. Allergy 1973, 3:143-160.
16. Cullinan P., et al. An outbreak of asthma in a modern detergent factory. Lancet 2000, 356:1899-1900.
17. Baur X., Fruhmann G. Allergic reactions, including asthma, to the pineapple protease bromelain following occupational exposure. Clin. Allergy 1979, 9:443-450.
18. Burrows B., et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N. Engl. J. Med. 1989, 320:271-277.
19. Sporik R., et al. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N. Engl. J. Med. 1990, 323:502-507.
20. Wan H., et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J. Clin. Invest. 1999, 104:123-133.
21. Gough L., et al. The cysteine protease activity of the major dust mite allergen Der p 1 selectively enhances the immunoglobulin E antibody response. J. Exp. Med. 1999, 190:1897-1902.
22. Schulz O., et al. Proteolytic cleavage of CD25, the alpha subunit of the human T cell interleukin 2 receptor, by Der p 1, a major mite allergen with cysteine protease activity. J. Exp. Med. 1998, 187:271-275.
23. King C., et al. Dust mite proteolytic allergens induce cytokine release from cultured airway epithelium. J. Immunol. 1998, 161:3645-3651.
24. Tsitoura D.C., et al. Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J. Immunol. 1999, 163:2592-2600.
25. Akbari O., et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. 2002, 8:1024-1032.
26. Corry D.B., Irvin C.G. Promise and pitfalls in animal-based asthma research: Building a better mousetrap. Immunol. Res. 2006, 35:279-294.
27. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
28. Medzhitov R., et al. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397.
29. Kopp E.B., Medzhitov R. The Toll-receptor family and control of innate immunity. Curr. Opin. Immunol. 1999, 11:13-18.
30. Schnare M., et al. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2001, 2:947-950.
31. Kim Y.G., et al. The cytosolic sensors Nod1 and Nod2 are critical for bacterial recognition and host defense after exposure to Toll-like receptor ligands. Immunity 2008, 28:246-257.
32. Ramet M., et al. Drosophila scavenger receptor CI is a pattern recognition receptor for bacteria. Immunity 2001, 15:1027-1038.
33. Thomas C.A., et al. Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J. Exp. Med. 2000, 191:147-156.
34. Eisenbarth S.C., et al. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J. Exp. Med. 2002, 196:1645-1651.
35. Dabbagh K., et al. Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells. J. Immunol. 2002, 168:4524-4530.
36. Wan G.H., et al. Airborne endotoxin exposure and the development of airway antigen-specific allergic responses. Clin. Exp. Allergy 2000, 30:426-432.
37. Redecke V., et al. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J. Immunol. 2004, 172:2739-2743.
38. Bortolatto J., et al. Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis. Clin. Exp. Allergy 2008, 38:1668-1679.
39. Rodriguez D., et al. Bacterial lipopolysaccharide signaling through Toll-like receptor 4 suppresses asthma-like responses via nitric oxide synthase 2 activity. J. Immunol. 2003, 171:1001-1008.
40. Velasco G., et al. Toll-like receptor 4 or 2 agonists decrease allergic inflammation. Am. J. Respir. Cell Mol. Biol. 2005, 32:218-224.
41. Watanabe J., et al. Endotoxin contamination of ovalbumin suppresses murine immunologic responses and development of airway hyper-reactivity. J. Biol. Chem. 2003, 278:42361-42368.
42. Kheradmand F., et al. A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. J. Immunol. 2002, 169:5904-5911.
43. Porter P., et al. Link between allergic asthma and airway mucosal infection suggested by proteinase-secreting household fungi. Mucosal Immunol. 2009, 2:504-517.
44. Singh M., et al. Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2010, 125:1369-1378.
45. Cates E.C., et al. Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM-CSF-mediated mechanism. J. Immunol. 2004, 173:6384-6392.
46. Sokol C.L., et al. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat. Immunol. 2008, 9:310-318.
47. Kukreja N., et al. Effect of proteolytic activity of Epicoccum purpurascens major allergen, Epi p 1 in allergic inflammation. Clin. Exp. Allergy 2008, 154:162-171.
48. Sudha V.T., et al. Identification of a serine protease as a major allergen (Per a 10) of Periplaneta americana. Allergy 2008, 63:768-776.
49. Kolattukudy P.E., et al. Evidence for possible involvement of an elastolytic serine protease in aspergillosis. Infect. Immun. 1993, 61:2357-2368.
50. Smith J.M., et al. Virulence of Aspergillus fumigatus double mutants lacking restriction and an alkaline protease in a low-dose model of invasive pulmonary aspergillosis. Infect. Immun. 1994, 62:5247-5254.
51. Mattila P.E., et al. Dectin-1 Fc targeting of Aspergillus fumigatus beta-glucans augments innate defense against invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 2008, 52:1171-1172.
52. Reese T.A., et al. Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature 2007, 447:92-96.
53. Wan G.H., et al. An airbone mold-derived product, β-1,3-d-glucan, potentiates airway allergic responses. Eur. J. Immunol. 1999, 29:2491-2497.
54. Yoon J., et al. Innate antifungal immunity of human eosinophils mediated by a beta 2 integrin, CD11b. J. Immunol. 2008, 181:2907-2915.
55. Mattern I.E., et al. Isolation and characterization of mutants of Aspergillus niger deficient in extracellular proteases. Mol. Gen. Genet. 1992, 234:332-336.
56. Shakib F., et al. A mite subversive: cleavage of CD23 and CD25 by Der p 1 enhances allergenicity. Immunol. Today 1998, 19:313-316.
57. Schmidlin F., et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J. Immunol. 2002, 169:5315-5321.
58. Drouin S.M., et al. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J. Immunol. 2002, 169:5926-5933.
59. Drouin S.M., et al. Cutting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy. J. Immunol. 2001, 167:4141-4145.
60. Trinchieri G., et al. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Prog. Growth Factor Res. 1992, 4:355-368.
61. Goswami S., et al. Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma. Nat. Immunol. 2009, 10:496-503.
62. Postma D.S., et al. Genetic susceptibility to asthma-bronchial hyperresponsiveness coinherited with a major gene for atopy. N. Engl. J. Med. 1995, 333:894-900.
63. Mansur A.H., et al. Association study of asthma and atopy traits and chromosome 5q cytokine cluster markers. Clin. Exp. Allergy 1998, 28:141-150.
64. Kabesch M., et al. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. J. Allergy Clin. Immunol. 2006, 117:269-274.
65. Guerra S., et al. Rhinitis as an independent risk factor for adult-onset asthma. J. Allergy Clin. Immunol. 2002, 109:419-425.
66. Chen Y., et al. The epidemiology of chronic rhinosinusitis in Canadians. Laryngoscope 2003, 113:1199-1205.
67. Tang P., et al. Allergic fungal sinusitis associated with Trichoderma longibrachiatum. J. Clin. Microbiol. 2003, 41:5333-5336.
68. Tosca M.A., et al. Improvement of clinical and immunopathologic parameters in asthmatic children treated for concomitant chronic rhinosinusitis. Ann. Allergy Asthma Immunol. 2003, 91:71-78.
69. Tsao C.H., et al. Concomitant chronic sinusitis treatment in children with mild asthma: the effect on bronchial hyperresponsiveness. Chest 2003, 123:757-764.
70. Ponikau J.U., et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin. Proc. 1999, 74:877-884.
71. Shin S.-H., et al. Chronic rhinosinusitis: an enhanced immune response to ubiquitous airborne fungi. J. Allergy Clin. Immunol. 2004, 114:1369-1375.
72. Carney A.S., et al. Th2 immunological inflammation in allergic fungal sinusitis, nonallergic eosinophilic fungal sinusitis, and chronic rhinosinusitis. Am. J. Rhinol. 2006, 20:145-149.
73. Vallor A.C., et al. Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob. Agents Chemother. 2008, 52:2593-2598.
74. Borish L., et al. Fungi in chronic hyperplastic eosinophilic sinusitis: reasonable doubt. Clin. Rev. Allergy Immunol. 2006, 30:195-204.
75. Luong A., et al. Peripheral blood mononuclear cells from allergic fungal rhinosinusitis adults express a Th2 cytokine response to fungal antigens. Am. J. Rhinol. Allergy 2009, 23:281-287.
76. Ward G.W., et al. Treatment of late-onset asthma with fluconazole. J. Allergy Clin. Immunol. 1999, 104:541-546.
77. Denning D.W., et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am. J. Respir. Crit. Care Med. 2009, 179:11-18.
78. Pasqualotto A.C., et al. The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. Respirology 2009, 14:1121-1127.
79. Vicencio A.G., et al. Severe asthma with fungal sensitization in a child: response to itraconazole therapy. Pediatrics 2010, 125:e1255-e1258.
80. Lemanske R.F., Busse W.W. Asthma. J. Am. Med. Assoc. 1997, 278:1855-1873.
81. Humbert M., et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am. J. Respir. Crit. Care Med. 1996, 154:1497-1504.